Tyrosine Supplementation Rescues a Growth Defect in a Humanized S. cerevisiae Model of YARS1 Associated with CMT-DI.

doi:10.3390/ijms27167481

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Tyrosine Supplementation Rescues a Growth Defect in a Humanized S. cerevisiae Model of YARS1 Associated with CMT-DI.

International journal of molecular sciences - 21 Aug 2026

Sun Nancy, Samuels Tristan N, Hoffman Kyle, Busari Ridhwan, Nasir Zain, Girard Nicole, Reynolds Noah M, Heinemann Ilka U

Abstract excerpt

Dominant pathogenic mutations in tyrosyl-tRNA synthetase (YARS1) are associated with Charcot-Marie-Tooth disease (CMT), a progressive peripheral neuropathy for which no disease-modifying therapies currently exist. While recent advances in amino acid supplementation therapies suggest potential benefit for recessive aminoacyl-tRNA synthetase disorders, their applicability to dominant YARS1-associated neuropathies...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Charcot-Marie-Tooth Disease
Share to Mutation
Share to Saccharomyces cerevisiae

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Tyrosine

Share to Tyrosine-tRNA Ligase

Source

Open in PubMed Open full text

Identifiers

PMID: 42653481
DOI: 10.3390/ijms27167481
PMCID: PMC13513244

Genes

YARS1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.